Journal Mobile Options
Table of Contents
Vol. 3, No. 1, 2011
Issue release date: January – April
Open Access Gateway
Case Rep Dermatol 2011;3:32–36
(DOI:10.1159/000324721)

Giant Hemosiderotic Dermatofibroma: A Case Report and Review of the Literature

Pusztaszeri M.a · Jaquet P.-Y.b · Williamson C.c
aDivision of Clinical Pathology, Geneva University Hospital, Geneva, bGeneral Practitioner, Bassins, and cPathology and Cytology Laboratory, Unilabs-Cytopath, Geneva, Switzerland
email Corresponding Author

Abstract

Dermatofibroma is a common benign fibrohistiocytic lesion that usually appears as a slow-growing, firm dermal nodule with a predilection for the legs of middle-aged women. They are usually smaller than 2 cm in diameter. Many histological variants have been described. Generally, the clinical and histological diagnosis is straightforward, but differentiating it from other cutaneous tumors can be difficult in atypical cases and rare variants. Giant dermatofibroma is a rare clinical variant of dermatofibroma and less than 25 cases have been reported. It is characterized essentially by its unusually large size, which often mimics malignant tumors clinically. We first present the case of a giant hemosiderotic dermatofibroma in a 54-year-old patient, who presented with a large ulcerated mass of the left foot which was excised, and then review the literature briefly.


 Outline


 goto top of outline Key Words

  • Giant dermatofibroma
  • Hemosiderotic dermatofibroma
  • Fibrous histiocytoma

 goto top of outline Abstract

Dermatofibroma is a common benign fibrohistiocytic lesion that usually appears as a slow-growing, firm dermal nodule with a predilection for the legs of middle-aged women. They are usually smaller than 2 cm in diameter. Many histological variants have been described. Generally, the clinical and histological diagnosis is straightforward, but differentiating it from other cutaneous tumors can be difficult in atypical cases and rare variants. Giant dermatofibroma is a rare clinical variant of dermatofibroma and less than 25 cases have been reported. It is characterized essentially by its unusually large size, which often mimics malignant tumors clinically. We first present the case of a giant hemosiderotic dermatofibroma in a 54-year-old patient, who presented with a large ulcerated mass of the left foot which was excised, and then review the literature briefly.

Copyright © 2011 S. Karger AG, Basel


 goto top of outline Author Contacts

Marc Pusztaszeri, MD
Service de Pathologie Clinique (CMU)
1 Rue Michel Servet
CH–1211 Genève 4 (Switzerland)
Tel. +41 223 728 574, E-Mail Marc.Pusztaszeri@hcuge.ch


 goto top of outline Article Information

Published online: February 18, 2011
Number of Print Pages : 5
Number of Figures : 3,


 goto top of outline Publication Details

Case Reports in Dermatology

Vol. 3, No. 1, Year 2011 (Cover Date: January - April)

Journal Editor: Jemec G. (Roskilde)
ISSN: NIL (Print), eISSN: 1662-6567 (Online)

For additional information: http://www.karger.com/CDE


Open Access License / Drug Dosage / Disclaimer

Open Access License: This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to the online version of the article only. Distribution permitted for non-commercial purposes only.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Abstract

Dermatofibroma is a common benign fibrohistiocytic lesion that usually appears as a slow-growing, firm dermal nodule with a predilection for the legs of middle-aged women. They are usually smaller than 2 cm in diameter. Many histological variants have been described. Generally, the clinical and histological diagnosis is straightforward, but differentiating it from other cutaneous tumors can be difficult in atypical cases and rare variants. Giant dermatofibroma is a rare clinical variant of dermatofibroma and less than 25 cases have been reported. It is characterized essentially by its unusually large size, which often mimics malignant tumors clinically. We first present the case of a giant hemosiderotic dermatofibroma in a 54-year-old patient, who presented with a large ulcerated mass of the left foot which was excised, and then review the literature briefly.



 goto top of outline Author Contacts

Marc Pusztaszeri, MD
Service de Pathologie Clinique (CMU)
1 Rue Michel Servet
CH–1211 Genève 4 (Switzerland)
Tel. +41 223 728 574, E-Mail Marc.Pusztaszeri@hcuge.ch


 goto top of outline Article Information

Published online: February 18, 2011
Number of Print Pages : 5
Number of Figures : 3,


 goto top of outline Publication Details

Case Reports in Dermatology

Vol. 3, No. 1, Year 2011 (Cover Date: January - April)

Journal Editor: Jemec G. (Roskilde)
ISSN: NIL (Print), eISSN: 1662-6567 (Online)

For additional information: http://www.karger.com/CDE


Open Access License / Drug Dosage

Open Access License: This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to the online version of the article only. Distribution permitted for non-commercial purposes only.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.